Literature DB >> 31912365

Aggressive pituitary tumors in the young and elderly.

Christina Tatsi1, Constantine A Stratakis2.   

Abstract

Aggressive pituitary tumors (APTs) represent rare pituitary adenomas (PAs) with local invasion of surrounding tissues, increased risk for multiple recurrence, rapid tumor growth, or resistance to standard therapies. The most common APTs in children and adolescents are giant prolactinomas and somatotropinomas. Few cases of Crooke's cell adenomas, silent corticotroph adenomas and pituitary carcinomas have also been reported in the literature. Pediatric patients with APTs have higher risk of harboring germline genetic defects, most commonly in the MEN1 and AIP genes. Since certain genetic defects confer a more aggressive behavior to PAs, genetic testing should be considered in tumors with young onset and positive family history. The management of pediatric APTs involves usually a combination of standard therapies (surgical, medical, radiation). Newer agents, such as temozolomide, have been used in few cases of pediatric pituitary tumors with promising results. In the elderly, PAs are more commonly non-functioning. Their management often poses dilemmas given the coexistence of age-related comorbidities. However, standard surgical treatment and temozolomide seem to be safe and well tolerated in elderly patients.

Entities:  

Keywords:  Adenoma; Adolescent; Aggressive; Children; Pituitary

Year:  2020        PMID: 31912365     DOI: 10.1007/s11154-019-09534-8

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  10 in total

1.  High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors.

Authors:  Wenxiu Zhao; Xiaobin Jiang; Karrin Weisenthal; Jun Ma; Erin M Botticelli; Yunli Zhou; E Tessa Hedley-Whyte; Baiyao Wang; Brooke Swearingen; Roy J Soberman; Anne Klibanski; Xun Zhang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

2.  Characteristics and overall survival in pediatric versus adult pituitary adenoma: a National Cancer Database analysis.

Authors:  Benjamin F Bitner; Brandon M Lehrich; Arash Abiri; Tyler M Yasaka; Frank P K Hsu; Edward C Kuan
Journal:  Pituitary       Date:  2021-04-30       Impact factor: 4.107

Review 3.  High-risk pituitary adenomas and strategies for predicting response to treatment.

Authors:  George Kontogeorgos; Eleni Thodou; Robert Y Osamura; Ricardo V Lloyd
Journal:  Hormones (Athens)       Date:  2022-01-21       Impact factor: 2.885

4.  Long-Term Use of Temozolomide as Safe and Effective Therapy for an Aggressive Corticotroph Adenoma in a Very Old Patient.

Authors:  Maria Chiara Decaroli; Anna Ansaloni; Maria Laura Monzani; Marco Losa; Elena Zunarelli; Vincenzo Rochira; Bruno Madeo
Journal:  J Endocr Soc       Date:  2021-04-10

5.  Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up.

Authors:  Isabella Naves Rosa; Alexandre Anderson de Sousa Munhoz Soares; Marcelo Palmeira Rodrigues; Luciana Ansaneli Naves
Journal:  Clin Diabetes Endocrinol       Date:  2021-03-17

6.  PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.

Authors:  Kejing Zhu; Xueting Cheng; Shuman Wang; Hong Zhang; Yu Zhang; Xiong Wang; Yonggang Chen; Jinhu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-21       Impact factor: 5.555

7.  Pituitary adenomas in the elderly: Retrospective comparative analysis of clinical/tumor features and surgical data by age group.

Authors:  Patrícia Rosinha; Liliana Fonseca; Cláudia Amaral; Isabel Ribeiro; Maria Helena Cardoso
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

Review 8.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

Review 9.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

10.  A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.

Authors:  Yu Zhang; Yuqi Luo; Xin Kong; Tao Wan; Yunling Long; Jun Ma
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.